Startup
Specific Biologics
Toronto biotechnology company developing Dualase genome-editing medicines for genetic diseases.
Key details
- Profile type
- Organization
- Geography
- Toronto, Ontario, Canada
- Stage
- Not publicly stated
- Sector
- Biotechnology and gene editing
- Founder groups
- Not publicly stated
- Last verified
- Nov 3, 2026
About Specific Biologics
Specific Biologics is a Toronto biotechnology company developing Dualase, a genome-editing platform designed to remove, repair or insert DNA sequences. Its development pipeline includes programs for repeat expansion disorders, cystic fibrosis and liver disease. On November 2, 2026, the company announced that it had closed a US$35 million Series A led by Hatteras Venture Partners. The company says the financing will support development of its lead candidate for C9ORF72-associated ALS toward initial clinical biomarker proof-of-concept. The candidate remains in development.
Official source
TorontoStarts does not endorse or rank this record. Confirm current details with the official source.
Check current details